DrugPipeline.net has announced the addition of “Graft Versus Host Disease (GVHD) - Epidemiology Insights-2023” research report to their website DrugPipeline.net
Bangalore, Karnataka -- (SBWIRE) -- 02/28/2017 -- "Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-Global" report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023) in the 7MM.
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). Publisher forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to Publisher's estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.80% from 2013-2023.
The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per Publisher forecasts, the global diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 2.63% and 2.51%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors for the 7MM is expected to accentuate at a CAGR of 1.96% and 1.57%, respectively, by the end of the year 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
- Report covers the disease overview including pathophysiology, symptoms, diagnosis and disease management.
- It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants (HSCTs) (which also includes the cases of first transplants along with the total transplants) in the 7MM.
- The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors (Sibling donors and unrelated donors) for the 7MM i.e., U.S., EU5 countries(Germany, France, Italy, Spain and United Kingdom) and Japan from 2013-2023.
Spanning over 70 pages "Graft Versus Host Disease (GVHD) - Epidemiology Insights-2023" report covers Graft Versus Host Disease (GVHD), Disease Definition, Disease Types, Appendix, Report Methodology.
For more information Visit at: http://www.drugpipeline.net/delveinsight/graft-versus-host-disease-gvhd-epidemiology-insights-2023
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.